

March 28, 2025

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform you that IGI Inc., i.e. wholly owned subsidiary of Glenmark Pharmaceuticals Limited ("the Company") has announced its plans to cease all CMC development and clinical supplies manufacturing at its facility in La Chaux-de-Fonds, Switzerland.

In accordance with the Listing Regulations and SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the disclosure by listed entities under Regulation 30 of the Listing Regulations, we are providing the details of the intended closure of the aforementioned manufacturing facility herein below:

1. Date of such binding agreement, if any, entered for sale of such unit/division, if any - Not Applicable
2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year –  
Turnover of plant - Rs. NIL (material is only used for captive consumption)  
Percentage to consolidated turnover of Company (1 April 2023 to 31 March 2024): NA  
Net worth of plant – Rs. 223.52 million (as of 31 March 2024)
3. Estimated date of closure - 31 July 2025
4. Reasons for closure – IGI is progressing its pipeline and it is anticipated that higher quantities of finished product will be required for future clinical programs. IGI CMC development and manufacturing of ongoing and future clinical programs will be moved to a network of well-established Contract Development and Manufacturing Organizations (CDMOs).
5. This closure will not adversely affect the Consolidated financials of the Company.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com